Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

MAHONEY DAVID L

Guyer William

Maduck Sean

Lyon Joseph Douglas

Professional Trader, 10+ years experience - Founder at https://t.co/oHBJyNQTZd and https://t.co/GEJpgVvdaY.

Alex Desjardins

Hybrid Position/Swing Trader, Cancer Survivor, Father, Brother, Uncle, Wine lover and Windsurfer. All opinions are my own and not investment advice.

Jonathan Whitcraft

I have seen the stock market change people's lives! It can change yours too. Never Give Up! You may find my best stock ideas at: https://t.co/rqfRosoA4A

Corcept Therapeutics Incorporated (CORT) Stock Price, Analysis & Trade Signals